Retlirafusp Alfa Plus SOX and Intraperitoneal Nab-Paclitaxel for Advanced Gastric/GEJ Cancer With Malignant Ascites

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
To evaluate the efficacy and safety of retlirafusp alfa in combination with SOX chemotherapy and intraperitoneal nab-paclitaxel as first-line treatment for advanced gastric/gastroesophageal junction (GC/GEJ) adenocarcinoma with malignant ascites, and to explore potential biomarkers associated with treatment response.
Epistemonikos ID: 9f13459e12ae97f9383fe9baa0aaca2100416528
First added on: Oct 03, 2026